


PHARMACEUTICAL 2022

Dare Bioscience Inc. Rank 286 of 466







PHARMACEUTICAL 2022

Dare Bioscience Inc. Rank 286 of 466



The relative strengths and weaknesses of Dare Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dare Bioscience Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Dare Bioscience Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 77%, being 1.3% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	55,296
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,053
Liabilities, Non-Current	1,000
Other Assets	485
Other Compr. Net Income	-64
Other Expenses	100
Other Liabilities	0
Other Net Income	372
Other Revenues	0
Property and Equipment	26
Research and Development	30,618
Selling, General and Administrative Expense	8,351

Output Variable	Value in 1000 USD
Assets	55,807
Liabilities	17,053
Expenses	39,069
Revenues	0
Stockholders Equity	38,754
Net Income	-38,696
Comprehensive Net Income	-38,728
Economic Capital Ratio	77%

